Reliability and Analysis of Symptom Category Scores of the Behavior Pathology in Alzheimer's Disease Rating Scale, Korean Version(BEHAVE-AD-K).
- Author:
Guk Hee SUH
1
;
Hyun Gyun SON
;
Hyongju SHIN
;
In Myoung KIM
;
Sangeui HONG
;
Jonghan PARK
;
Ihn Geun CHOI
;
Sang Kook KIM
;
Byeong Kil YEON
Author Information
1. Department of Psychiatry, Hangang Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. suhgh@chollian.net
- Publication Type:Original Article
- Keywords:
Alzheimer's disease;
Dementia;
Behavioral disturbances;
Psychosis;
Behavioral pathology
- MeSH:
Aged;
Alzheimer Disease*;
Behavioral Symptoms;
Cross-Sectional Studies;
Dementia;
Hospitals, Psychiatric;
Humans;
Pathology*;
Psychotic Disorders;
Reproducibility of Results
- From:Journal of Korean Geriatric Psychiatry
2001;5(1):50-57
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aims of this study were to (1) validate the inter-rater reliability of the BEHAVE-AD, Korean version, to (2) analyze the quantitative relationship between severity of Alzheimer's disease (AD) and mean scores on each of the BEHAVE-AD categories and mean total BEHAVE-AD score. DESIGN: Cross-sectional study of geriatric patients with AD evaluated at a mental hospital for the elderly. SAMPLE: Fifty-two consecutive patients diagnosed with probable Alzheimer's disease (AD) according to NINCDS-ADRDA diagnostic criteria. RESULTS: In reliability study, significant correlations were obtained for all BEHAVE-AD symptoms category scores and for mean total BEHAVE-AD scores. Analysis of BEHAVE-AD scores as a function of disease severity demonstrated a non-linear relationship between severity of behavioral symptoms and the global and cognitive advance of AD. Score analysis of the BEHAVE-AD indicates that these behavioral disturbances become most severe in the moderate and moderately severe stages of AD. CONCLUSION: All the results proved the cross-cultural validity and reliability of the BEHAVE-AD, Korean version. Furthermore, these results have implications for the methodology of pharmacological trials of putative cognitive enhancer compounds in AD.
